GlaxoSmithKline (GSK) confirmed it is reviewing roles at its Barnard Castle site as part of operational cuts over a three-year period.

Helen has expressed her sincere disappointment that valued jobs in her constituency are being put at risk.

Helen said: “GSK has committed to a long-term future in Barnard Castle, and are building new production facilities to be ready in the next few years. These job losses are part of a cost-cutting exercise and very disappointing.

“By coincidence last week the Business, Energy and Industrial Strategy (BEIS) select committee published a report on Brexit and pharmaceuticals. A few months ago the chairman of GSK told me that Brexit would add £50million to their costs.

“This is a clear argument of why the UK must commit to staying in the customs union and European Medicines Agency to strengthen our position in the UK and protect jobs.”

Link to Instagram Link to Twitter Link to YouTube Link to Facebook Link to LinkedIn Link to Snapchat Close Fax Website Location Phone Email Calendar Building Search